Cognito HOPE pivotal trial fully enrolled — 670 Alzheimer's patients, top-line data expected 2026, 2027 commercial launch target
Summary
Cognito Therapeutics announced that the HOPE pivotal study (NCT05637801) — their definitive efficacy trial of the Spectris 40Hz gamma entrainment platform for Alzheimer's disease — is fully enrolled. The randomized trial enrolled approximately 670 patients who will receive daily treatment with either Spectris or a sham sensory stimulation system for 12 months, with efficacy outcomes measured on a composite cognitive and functional endpoint. Top-line data are anticipated later in 2026. This news accompanied the closing of the $105M oversubscribed Series C led by Morningside Ventures (Gerald Chan, founder and Cognito board chairman), IAG Capital Partners, and Starbloom Capital, with new investors Apollo Health Ventures, New Vintage, and Benvolio Group. CEO Christian Howell described Spectris as potentially "the world's first physician-prescribed, at-home neuroprotective therapy for patients diagnosed with Alzheimer's."
Why it matters
Full enrollment of 670 patients in the HOPE pivotal trial is the most important single clinical milestone in Alzheimer's device history. The OVERTURE feasibility study was not powered to show statistical efficacy — HOPE is the definitive efficacy test. With data expected in 2026 and FDA submission and 2027 commercial launch planned, HOPE is the pivotal moment that will determine whether gamma entrainment joins lecanemab and donanemab as Alzheimer's disease-modifying therapies. A positive HOPE result would be transformative for the entire non-pharmacological brain health field.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial